The present invention relates to an improved method of providing photoreceptor function to a cell, for example for use in the treatment of retinal degeneration. The present invention also relates to compositions and kits, in particular for use in such methods.

The present invention relates to an improved method of providing photoreceptor function to a cell, for example for use in the treatment of retinal degeneration. The present invention also relates to compositions and kits, in particular for use in such methods.

The present invention provides a method of producing a heparan sulfate having an anticoagulant activity. Specifically, the present invention provides the method of producing a heparan sulfate having a desired molecular weight, by partially N-deacetylating a heparosan followed by depolymerizing the heparosan by heparinase III, and converting the produced low molecular weight product into heparan sulfate having an anticoagulant activity.

A therapeutic agent containing, as an effective component, a glycolytic enzyme which is different from a deficient protein of a patient with lysosomal storage disease as a subject and/or a glycolytic enzyme which does not have a mannose 6-phosphate moiety or a mannose moiety.

A method for inhibiting metastasis of cancer cells is provided. Inhibitors of heparan sulfate (HS) or hyaluronic acid (HA) are applied to a tumor or a surgical location after removal of the bulk of the tumor. The inhibitors enzymatically cleave surface HS or HA; genetically modify cancer cells to decrease HS or HA production or interfere with the signaling pathway between HS or HA and a MMP or syndecan.

The present invention provides a method of producing a heparan sulfate having an anticoagulant activity. Specifically, the present invention provides the method of producing a heparan sulfate having a desired molecular weight, by partially N-deacetylating a heparosan followed by depolymerizing the heparosan by heparinase III, and converting the produced low molecular weight product into heparan sulfate having an anticoagulant activity.

The present invention relates to the use of agents (including heparin derivatives) for the prevention and/or treatment of CNS damage.